Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L611461-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $550.90 | |
L611461-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,900.90 |
Synonyms | Lazucirnon|ALK4290|ALK-4290|AKST4290|1251528-23-0|Lazucirnon [USAN]|ALK429|AKST-4290|R0T9LLR4TN|BI144807|ALK-429|Lazucirnon (USAN)|2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N,N,6-trimethylpyridine-4- |
---|---|
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of CCR3 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N,N,6-trimethylpyridine-4-carboxamide |
---|---|
INCHI | InChI=1S/C27H34ClN5O3/c1-17-13-19(5-6-22(17)28)16-32-11-9-21(10-12-32)33-23(7-8-25(33)34)26(35)30-24-15-20(14-18(2)29-24)27(36)31(3)4/h5-6,13-15,21,23H,7-12,16H2,1-4H3,(H,29,30,35)/t23-/m1/s1 |
InChi Key | DWKNOLCXIFYNFV-HSZRJFAPSA-N |
Canonical SMILES | O=C([C@H]1CCC(=O)N1C1CCN(CC1)Cc1ccc(c(c1)C)Cl)Nc1nc(C)cc(c1)C(=O)N(C)C |
Isomeric SMILES | CC1=CC(=CC(=N1)NC(=O)[C@H]2CCC(=O)N2C3CCN(CC3)CC4=CC(=C(C=C4)Cl)C)C(=O)N(C)C |
PubChem CID | 59534386 |
PubChem CID | 59534386 |
---|---|
ChEMBL Ligand | CHEMBL3670800 |
CAS Registry No. | 1251528-23-0 |
GPCRdb Ligand | lazucirnon |
Enter Lot Number to search for COA:
1. Hirahara S, Nozaki M, Ohbayashi M, Hasegawa N, Ozone D, Ogura Y. (2017) Suppression of Retinal Neovascularization by Anti-CCR3 Treatment in an Oxygen-Induced Retinopathy Model in Mice.. Ophthalmic Res, 58 (1): (56-66). [PMID:28376500] |
2. Zhu C, Xu B, Sun X, Zhu Q, Sui Y. (2017) Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease.. Mol Neurobiol, 54 (10): (7964-7978). [PMID:27878757] |
3. Gauvreau GM, FitzGerald JM, Boulet LP, Watson RM, Hui L, Villineuve H, Scime TX, Schlatman AR, Obminski C, Kum J et al.. (2018) The effects of a CCR3 inhibitor, AXP1275, on allergen-induced airway responses in adults with mild-to-moderate atopic asthma.. Clin Exp Allergy, 48 (4): (445-451). [PMID:29423947] |
4. Grozdanovic M, Laffey KG, Abdelkarim H, Hitchinson B, Harijith A, Moon HG, Park GY, Rousslang LK, Masterson JC, Furuta GT et al.. (2019) Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness.. J Allergy Clin Immunol, 143 (2): (669-680.e12). [PMID:29778505] |
5. Filippone RT, Robinson AM, Jovanovska V, Stavely R, Apostolopoulos V, Bornstein JC, Nurgali K. (2018) Targeting eotaxin-1 and CCR3 receptor alleviates enteric neuropathy and colonic dysfunction in TNBS-induced colitis in guinea pigs.. Neurogastroenterol Motil, 30 (11): (e13391). [PMID:29968270] |
6. Sui Y, Zhang Y, Dong C, Xu B, Sun X. (2019) The small molecular CCR3 antagonist YM344031 attenuates neurodegenerative pathologies and improves learning and memory performance in a mouse model of Alzheimer's disease.. Brain Res, 1719 (3): (1-10). [PMID:31121157] |